Uncategorized

Today we are presenting new data from our ALN-AT3 program for the treatment of hemophilia and other bleeding disorders at the 54th American Society of Hematology (ASH) Annual Meeting in Atlanta. ALN-AT3 comprises part of our “Alnylam 5x15™” strategy, which is aimed at bringing innovative medicines to patients, with a focus on RNAi therapeutics toward genetically defined targets for diseases with very high unmet medical need. [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALNY-ASH-AT3posterXpanel-Dec2012-r.pdf" type="(2.3 MB PDF)"] View our poster [/spotlight-link] [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734078"  type=" "] Read our press release[/spotlight-link]

At the Liver Meeting held this week in Boston, our scientists presented pre-clinical data from our ALN-AAT program for the treatment of liver disease associated with alpha-1 antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic condition characterized by misfolding of mutant AAT (“Z-AAT”) that causes lung and liver disease. [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALNY-AASLD-AAT-Nov20121.pdf" type="(2.2 MB PDF)"]View our presentation[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALNY-AASLD-FibrosisPosterXPanel-Nov2012.pdf" type="(2.8 MB PDF)"]View our poster[/spotlight-link] [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734084" type=" "]Read our press release[/spotlight-link]

At the 8th Annual Meeting of the Oligonucleotide Therapeutics Society, held in Boston October 28-31, 2012, we presented exciting data covering several of the company’s therapeutic programs and delivery platforms. THERAPEUTIC PROGRAMS Therapeutic research highlighted recent clinical and pre-clinical work from our programs in transthyretin-mediated amyloidosis (TTR), hemophilia, hypercholesterolemia, and liver cancer. Click here for presentations.

New data from our conjugate delivery platform was presented at the XX International Roundtable on Nucleosides, Nucleotides and Nucleic Acids held in August 2012.  This delivery platform enables subcutaneous dose administration of RNAi therapeutics with a very wide therapeutic index.  We are integrating this approach...

At the World Federation of Hemophilia World Congress in July 2012, scientists presented pre-clinical data with ALN-AT3, our development candidate targeting antithrombin (AT) for the treatment of hemophilia.  The new data demonstrate potent and durable AT knockdown with subcutaneous administration of ALN-AT3.  ALN-AT3 was shown to improve thrombin generation in hemophilia animal models. [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALNY-WFH2012-AT3-Poster-PPT.pdf" type="(774 KB PDF)"]View our poster (slide format)[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALNY-WFH-AT3poster-July2012.pdf" type="(3.3 MB PDF)"]View our poster[/spotlight-link] [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734078" type=" "]View our  release[/spotlight-link]

At the annual ASCO meeting in June 2012, we presented data from our ALN-VSP Phase I extension study. Overall, the results demonstrated disease control lasting more than six months in the majority of patients treated on the extension study, including a complete response (CR) in an endometrial cancer patient who had multiple liver metastases. [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALN-VSP-ExtensionStudyPoster-ASCO-June2012-panel.pdf" type="(3.72 MB PDF)"]View our poster[/spotlight-link] [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734295" type=" "]View our  release[/spotlight-link]

Today, scientists presented final results from our Phase I clinical trial of ALN-TTRo1 at the XIII International Symposium on Amyloidosis held in Groningen. Data from this study show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels, including both wild-type and mutant TTR protein, in ATTR patients.  Knockdown of TTR, the disease-causing protein, was found to be dose dependent, rapid, and durable after just a single dose. [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALNY-IntlSympAmyloidosis-PhI-Update-May2012.pdf" type="(842 KB PDF)"]View our  presentation[/spotlight-link] [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734299" type=" "]View our  release[/spotlight-link] [spotlight-link icon="podcast" href="http://www.alnylam.com/web/assets/KOL-discussion-ALN-TTRprogram.mp3" type="(27.7MB MP3)"]Listen to KOL, Dr. Hawkins discuss the ALN-TTR program (recorded Jan. 2012)[/spotlight-link]

Yesterday, scientists presented positive results from our Phase I clinical trial of ALN-PCS at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions held in Chicago. Results showed that administration of a single dose of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins, resulted in statistically significant and durable reductions of PCSK9 plasma levels of up to 84% and lowering of LDL-C of up to 50%. [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALN-PCS-PhaseI-ATVB-April20-2012.pdf" type="(572 KB PDF)"]View our  presentation[/spotlight-link] [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734310" type="(572 KB PDF)"]Read our press release[/spotlight-link]

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.